Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
KDMF
0
VMF
0
FDF
0
Australia
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. 1-((4r,5r)-4,5-dihydroxy-n2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-l-ornithine)-echinocandin B
2. Eraxis
3. Ly 303366
4. Ly-303366
5. Ly303366
1. Eraxis
2. 166663-25-8
3. Ecalta
4. V-echinocandin
5. Ver-002
6. Ly303366
7. Ly-303366
8. Anidulafungin (ly303366)
9. Ver002
10. Chebi:55346
11. 9hlm53094i
12. D70013
13. D-70013
14. N-[(3s,6s,9s,11r,15s,18s,20r,21r,24s,25s,26s)-6-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1r)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-18-yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide
15. Anidulafungin [usan]
16. Anidulafungina
17. Anidulafungine
18. Anidulafunginum
19. Unii-9hlm53094i
20. Anidulafungin [usan:inn:ban]
21. Anidulafungin [mi]
22. Anidulafungin [inn]
23. Schembl38292
24. Anidulafungin [vandf]
25. (4r,5r)-4,5-dihydroxy-n(sup 2)-((4'-(pentyloxy)-p-terphenyl-4-yl)carbonyl)-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-l-threonyl-(3s,4s)-3-hydroxy-4-methyl-l-proline Cyclic (6-1)-peptide
26. Anidulafungin [mart.]
27. Anidulafungin [who-dd]
28. Chembl264241
29. Anidulafungin [ema Epar]
30. Anidulafungin [orange Book]
31. Bdbm50417554
32. Mfcd00917070
33. S4286
34. Ccg-270647
35. Cs-1824
36. Db00362
37. Ncgc00386349-01
38. Hy-13553
39. Sw222238-1
40. A13436
41. 663a258
42. J-010304
43. Q4764531
44. (4r,5r)-4,5-dihydroxy-n(sup 2)-((4''-(pentyloxy)-p-terphenyl-4-yl)carbonyl)-l-ornithyl-l-threonyl-trans-4-hydroxy-l-prolyl-(s)-4-hydroxy-4-(p-hydroxyphenyl)-l-threonyl-l-threonyl-(3s,4s)-3-hydroxy-4-methyl-l-proline Cyclic (6->1)-peptide
45. Echinocandin B, 1-((4r,5r)-4,5-dihydroxy-n(sup 2)-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-l-ornithine)-
46. Echinocandin B, 1-((4r,5r)-4,5-dihydroxy-n2-((4''-(pentyloxy)(1,1':4',1''-terphenyl)-4-yl)carbonyl)-l-ornithine)
47. N-[(3s,6s,9s,11r,15s,18s,20r,21r,24s,25s,26s)-6-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,21,25-tetrahydroxy-3,15-bis[(1r)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0^{9,13}]heptacosan-18-yl]-4-{4-[4-(pentyloxy)phenyl]phenyl}benzamide
48. N-[[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-tetrahydroxy-bis[(1r)-1-hydroxyethyl]-methyl-hexaoxo-[?]yl]-4-[4-(4-pentoxyphenyl)phenyl]benzamide
49. N-{(2r,6s,9s,11r,12r,14as,15s,16s,20s,23s,25as)-23-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,12,15-tetrahydroxy-6,20-bis[(1r)-1-hydroxyethyl]-16-methyl-5,8,14,19,22,25-hexaoxotetracosahydro-1h-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-4''-(pentyloxy)-1,1':4',1''-terphenyl-4-carboxamide
Molecular Weight | 1140.2 g/mol |
---|---|
Molecular Formula | C58H73N7O17 |
XLogP3 | 2.3 |
Hydrogen Bond Donor Count | 14 |
Hydrogen Bond Acceptor Count | 17 |
Rotatable Bond Count | 14 |
Exact Mass | 1139.50629389 g/mol |
Monoisotopic Mass | 1139.50629389 g/mol |
Topological Polar Surface Area | 377 Ų |
Heavy Atom Count | 82 |
Formal Charge | 0 |
Complexity | 2150 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 15 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 2 | |
---|---|
Drug Name | Eraxis |
PubMed Health | Anidulafungin (Injection) |
Drug Classes | Antifungal |
Drug Label | ERAXIS for Injection is a sterile, lyophilized product for intravenous (IV) infusion that contains anidulafungin. ERAXIS (anidulafungin) is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is... |
Active Ingredient | Anidulafungin |
Dosage Form | Injectable |
Route | injection; Iv (infusion) |
Strength | 100mg/vial; 50mg; 50mg/vial |
Market Status | Prescription |
Company | Pfizer; Vicuron |
2 of 2 | |
---|---|
Drug Name | Eraxis |
PubMed Health | Anidulafungin (Injection) |
Drug Classes | Antifungal |
Drug Label | ERAXIS for Injection is a sterile, lyophilized product for intravenous (IV) infusion that contains anidulafungin. ERAXIS (anidulafungin) is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is... |
Active Ingredient | Anidulafungin |
Dosage Form | Injectable |
Route | injection; Iv (infusion) |
Strength | 100mg/vial; 50mg; 50mg/vial |
Market Status | Prescription |
Company | Pfizer; Vicuron |
For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis), Aspergillus infections, and esophageal candidiasis. Also considered an alternative treatment for oropharyngeal canaidiasis.
FDA Label
Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years.
Anidulafungin is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. Anidulafungin is active in vitro against many Candida, as well as some Aspergillus. Like other echinocandins, anidulafungin is not active against Cryptococcus neoformans, Trichosporon, Fusarium, or zygomycetes.
Antifungal Agents
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)
J02AX06
J - Antiinfectives for systemic use
J02 - Antimycotics for systemic use
J02A - Antimycotics for systemic use
J02AX - Other antimycotics for systemic use
J02AX06 - Anidulafungin
Route of Elimination
Less than 1% of the administered radioactive dose was excreted in the urine. Anidulafungin is not hepatically metabolized.
Volume of Distribution
30 to 50 L
Clearance
1 L/h
Hepatic metabolism of anidulafungin has not been observed. Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 (CYP450) isoenzymes. Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ring-opened peptide that lacks antifungal activity.
40-50 hours
Anidulafungin is a semi-synthetic echinocandin with antifungal activity. Anidulafungin inhibits glucan synthase, an enzyme present in fungal, but not mammalian cells. This results in inhibition of the formation of 1,3-β-D-glucan, an essential component of the fungal cell wall, ultimately leading to osmotic instability and cell death.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32877
Submission : 2018-06-12
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32010
Submission : 2017-08-28
Status : Active
Type : II
Date of Issue : 2019-09-23
Valid Till : 2022-07-02
Written Confirmation Number : WC-0111
Address of the Firm : Plot No. 1482-1486, Trasad Road, Dholka, Dist- Ahmedabad
Date of Issue : 2021-04-12
Valid Till : 2024-01-28
Written Confirmation Number : WC-0256
Address of the Firm : N.H.8, Near Grid, Kabilpore, City Navasari-396424, Dist. Navsari, Gujarat
NDC Package Code : 65727-072
Start Marketing Date : 2016-08-11
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 62227-007
Start Marketing Date : 2015-07-27
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 68254-0013
Start Marketing Date : 2014-07-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1mg/mg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 68254-0014
Start Marketing Date : 2014-08-01
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1mg/mg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 0009-0043
Start Marketing Date : 2015-08-26
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 11722-054
Start Marketing Date : 2014-03-05
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (100kg/100kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Related Excipient Companies
Excipients by Applications
Global Sales Information
Dosage Form : Anidulafungina 100Mg 30Ml 1 Unit...
Dosage Strength : 1 vial EV 100 mg 30 ml
Price Per Pack (Euro) : 625.42
Published in :
Country : Italy
RX/OTC/DISCN : Class H
Dosage Form : Dry Sub
Dosage Strength : 100mg
Price Per Pack (Euro) : 336.12
Published in :
Country : Switzerland
RX/OTC/DISCN : Class A
Dosage Form : Dry Sub
Dosage Strength : 100mg
Price Per Pack (Euro) : 336.12
Published in :
Country : Switzerland
RX/OTC/DISCN : Class A
Dosage Form : Dry Sub
Dosage Strength : 100mg
Price Per Pack (Euro) : 336.12
Published in :
Country : Switzerland
RX/OTC/DISCN : Class A
Dosage Form : Dry Sub
Dosage Strength : 100mg
Price Per Pack (Euro) : 395.42
Published in :
Country : Switzerland
RX/OTC/DISCN : Class A
Dosage Form : Powder to concentrate to the inf...
Dosage Strength : 100 mg
Price Per Pack (Euro) : 522.74
Published in :
Country : Norway
RX/OTC/DISCN :
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?